Based on the understanding of the key role of specific targets in the pathogenesis of vitiligo, targeted therapeutic agents such as JAK, PDE-4 inhibitors, and anti-CD122 blocking antibodies have been developed to treat vitiligo disease (7). This evidence concerns the gene IL2RB and vitiligo.